Detail page

Knowledge Web

Person

Michael Schmitt (1966-)

Name	Michael Schmitt
Time	1966- (Date of birth and death)
Place	Neunkirchen (Saar) (Geburtsort) Ulm (Wirkungsort) Heidelberg (Wirkungsort) Deutschland
Gender	männlich
Academic degree	Prof. Dr. med.
Related	Klinikum Heidelberg Hämatologie (Thema)
Further information	11/1992 Promotion zum Dr. med.; 03/2004 Erlangung der Venia legendi für das Fach Innere Medizin; seit 01.09.2011 W3-Professor für Zelluläre Immuntherapie (Siebeneicher-Stiftungsprofessur) an der Universität Heidelberg; Hauptarbeitsgebiet: Tumorimmunologie; Leiter der Sektion Zell- und Immuntherapie, Abteilung Hämatologie, Onkologie und Rheumatologie, Universitätsklinikum Heidelberg
Source	Kürschner Gelehrte (2007)
Record type	Person
GND-Identifier	133177173
Record ID	133177173
Involved in show all Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience Antisemitismus in der Akademie : Otto Meyerhof - ein Forscherleben zwischen Ruhm und Vertreibung First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience Optimizations of anti-tumor efficacy during CD19-specific chimeric antigen receptor (CAR) T/NK-cell manufacturing Blockade of CD95/CD95L death signaling enhances CAR T cell persistence and antitumor efficacy Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis Enhancement of cytotoxicity, expansion and persistence of CD19.CAR-T cells via pre-sensitization of B cell malignancies by inhibitors of Bcl-2 family proteins Ibrutinib for improved chimeric antigen receptor T cell production for chronic lymphocytic leukemia patients Improvement of chimeric antigen receptor T cell therapy for patients with hematological malignancies Optimierung der Produktion von CD19-spezifischen chimären Antigenrezeptor-modifizierten T-Zellen von Patienten mit chronisch lymphatischer Leukämie Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies Cell-based immunotherapy approaches for multiple myeloma Signatures of T and B Cell development, functional responses and PD-1 upregulation after HCMV latent infections and reactivations in Nod.Rag.Gamma mice humanized with cord blood CD34+ cells Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34+ Cells Cell therapeutic approaches to immunosuppression after clinical kidney transplantation Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis Cytomegalievirus bei Nierentransplantation – Diagnose, Prävention und Management Immunonkologie im Fokus Antimykotische Prophylaxe bei Neutropenie und Immundefizienz Identifikation von immunogenen Antigenen bei der akuten myeloischen Leukämie zur Entwicklung einer Tumorvakzine Simultane Bestimmung neuer Parameter des Eisenstoffwechsels und der Erythrozytenüberlebenszeit

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Michael Schmitt (1966-)

Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma

Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation

First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience

Antisemitismus in der Akademie : Otto Meyerhof - ein Forscherleben zwischen Ruhm und Vertreibung

First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience

Optimizations of anti-tumor efficacy during CD19-specific chimeric antigen receptor (CAR) T/NK-cell manufacturing

Blockade of CD95/CD95L death signaling enhances CAR T cell persistence and antitumor efficacy

Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers

Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data

A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial

The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis

Enhancement of cytotoxicity, expansion and persistence of CD19.CAR-T cells via pre-sensitization of B cell malignancies by inhibitors of Bcl-2 family proteins

Ibrutinib for improved chimeric antigen receptor T cell production for chronic lymphocytic leukemia patients

Improvement of chimeric antigen receptor T cell therapy for patients with hematological malignancies

Optimierung der Produktion von CD19-spezifischen chimären Antigenrezeptor-modifizierten T-Zellen von Patienten mit chronisch lymphatischer Leukämie

Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells

Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies

Cell-based immunotherapy approaches for multiple myeloma

Signatures of T and B Cell development, functional responses and PD-1 upregulation after HCMV latent infections and reactivations in Nod.Rag.Gamma mice humanized with cord blood CD34+ cells

Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34+ Cells

Cell therapeutic approaches to immunosuppression after clinical kidney transplantation

Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis

Cytomegalievirus bei Nierentransplantation – Diagnose, Prävention und Management

Immunonkologie im Fokus

Antimykotische Prophylaxe bei Neutropenie und Immundefizienz

Identifikation von immunogenen Antigenen bei der akuten myeloischen Leukämie zur Entwicklung einer Tumorvakzine

Simultane Bestimmung neuer Parameter des Eisenstoffwechsels und der Erythrozytenüberlebenszeit